Nutex Health NASDAQ: NUTX reported lower third-quarter revenue and earnings despite a rise in hospital visits, as executives pointed to prior-year revenue adjustments tied to collections under the federal independent dispute resolution process.

Nutex's rebuilt balance sheet, with equity recovering from $60.4M in 2024Q3 to $435.6M in 2026Q3 and a debt-to-equity ratio falling from 3.80 to 0.67, suggests financial durability has improved materially.
Price trend, volume and key moving averages
Trailing total returns as of 11/18/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).
Check whether operating performance supports the current valuation.
Recent results and news deserve attention only when they alter the forward view.
| Quarter | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|
Q4 2026Latest Nov 5, 2026 | $5.71+3.1% vs $5.54 | $218M+1.3% vs $215M |
Q3 2026 Aug 6, 2026 | $9.38+89.5% vs $4.95 | $211M-2.0% vs $215M |
Q2 2026 Apr 30, 2026 | $6.52+63.4% vs $3.99 | $216M-5.0% vs $228M |
Q2 2026 Mar 5, 2026 | $1.61-71.0% vs $5.56 | $152M-41.4% vs $259M |
Nutex Health NASDAQ: NUTX reported lower third-quarter revenue and earnings despite a rise in hospital visits, as executives pointed to prior-year revenue adjustments tied to collections under the federal independent dispute resolution process.

Nutex Health Inc. (NUTX) came out with quarterly earnings of $5.71 per share, beating the Zacks Consensus Estimate of $5.53 per share. This compares to earnings of $7.76 per share a year ago.
HOUSTON, Nov. 5, 2026 /PRNewswire/ -- Nutex Health Inc. ("Nutex Health" or the "Company") (NASDAQ and Nasdaq Texas: NUTX), today announced financial results for the three and nine months ended September 30, 2026. Nutex Health is a physician-led, healthcare services and operations company with 28 hospital facilities in 12 states (hospital division), and a primary care-centric, risk-bearing population health management division.
Nutex Health's Q3 earnings face revenue pressure from reimbursement uncertainty, but rising patient volumes and lower arbitration costs may support profitability.
Benchmark NUTX against direct peers instead of judging its metrics in isolation.
Key metrics vs top competitors for Nutex Health, Inc. (NUTX)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $174.51 | $1.2B | 7.46 | 82.36% | 20.68% | 34.43% | 6.3% | |
| $121.56 | $2.27B | 20.33 | 23.21% | 7.39% | 9.81% | — | |
| $19.44 | $363.6M | 8.98 | 2.63% | 12.1% | 16.38% | 13.1% | |
| $191.98 | $11.62B | 7.77 | 9.71% | 7.96% | 19.27% | 0.41% | |
| $282.07 | $24.3B | 7.84 | 3.12% | 12.71% | 32.11% | — | |
| $2.02 | $284.84M | -0.53 | -1.18% | -2.34% | — | — |
Nutex Health, Inc. (NUTX) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
Verify the primary filings, follow material updates, and answer the remaining questions.
Nutex Health, Inc. (NUTX) SEC filings — annual & quarterly reports (10-K, 10-Q)
Nov 5, 2026·SEC
Aug 6, 2026·SEC
Jul 21, 2026·SEC
Get notified when NUTX posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
Nutex Health, Inc. (NUTX) stock FAQ — growth, dividends, profitability & financials explained
Nutex Health, Inc. (NUTX) reported $796.5M in revenue over the trailing twelve months. Revenue was $875.3M in fiscal year 2025. That is 69016% more than the $1.3M of fiscal year 2010.
Nutex Health, Inc. (NUTX) revenue fell by 18.8% over the trailing twelve months, compared with the twelve months before.
Yes. Nutex Health, Inc. (NUTX) earned $164.7M in net income over the trailing twelve months (a 20.7% net margin).
Yes. Nutex Health, Inc. (NUTX) pays a dividend that yields 6.30% at the current price, a high yield.
Nutex Health, Inc. (NUTX) had a return on equity (ROE) of 34.4% over the trailing twelve months. That is well above the market's typical 10-15%.
Nutex Health, Inc. (NUTX) generated $252.1M in free cash flow over the trailing twelve months.